Abstract
About this talk
Modern therapeutics are commonly studied through separate models of molecular binding, formulation, pharmacokinetics, cellular response, organ toxicity, and clinical monitoring. Such separation limits interpretation of how a chemical intervention becomes a patient-level therapeutic outcome. This presentation introduces a unified B-Chem–B-Bio–B-Pharma framework for multiscale disease modelling, drug delivery, and patient-specific therapeutic control, implemented as a research-oriented workflow within the Bvidal Clinical Software Suite. The framework represents therapy as a connected trajectory extending from molecular structure to clinically observable response. At the B-Chem level, drug–target interaction is described through molecular geometry, active-site accessibility, receptor or enzyme engagement, conformational compatibility, reaction-pathway control, and transition-state behaviour. At the B-Pharma level, formulation, administration, absorption, distribution, metabolism, excretion, protein binding, controlled release, drug–drug interaction, and dose–response behaviour are organized as coupled transport and pharmacological states. At the B-Bio level, these states are projected into cellular signalling, gene silencing or expression, oxidative stress, mitochondrial function, inflammation, apoptosis, immune response, tissue remodelling, disease progression, and multi-organ safety. The proposed model uses the common Bansal concepts of algebra, manifold, projection, trajectory, curvature, operators, holonomy, entropy, fiber bundle, tensor, and connection to organize molecular, cellular, tissue, organ, and clinical layers within one interpretable architecture. Therapeutic action is therefore not treated merely as a molecule binding to a target, but as a constrained state transition involving delivery efficiency, biological barrier crossing, intracellular release, target modulation, systemic exposure, beneficial response, adverse effects, and measurable clinical evidence. Bvidal Clinical Software Suite is used to organize imaging, bio signals, laboratory variables, pharmacokinetic measurements, omics evidence, and longitudinal observations into structured simulation and review outputs. Geometry-aware artificial intelligence is positioned as an assisting layer for multimodal integration, hidden-state estimation, missing-data handling, calibration, and patient-specific parameter inference rather than as an unrestricted black-box decision system. The work is intended as a proof-of-concept platform for computational pharmacology, nanomedicine, medicinal chemistry, disease modelling, and interpretable therapeutic simulation. It does not replace clinical judgment, prescribe treatment, or claim regulatory validation. Its central objective is to provide a transparent pathway from molecular interaction and therapeutic transport to disease modification, organ response, clinical observation, and personalized control. By preserving the distinction between internal modelled states and observable measurements, the approach supports traceable explanation of why two patients receiving the same drug may exhibit different exposure, efficacy, toxicity, or recovery patterns. The presentation emphasizes reproducible public-dataset demonstrations, explicit assumptions, uncertainty-aware outputs, and modular expansion toward additional formulations, diseases, biomarkers, and therapeutic strategies while retaining clinician-led interpretation and safety oversight throughout development.
Speaker
About the speaker

